681808-48-0

Basic information

• Product Name: Cyclopropanecarboxamide, 1-(aminosulfonyl)-N-(3,5-dimethyl-4-isoxazolyl)-
• Synonyms: Cyclopropanecarboxamide, 1-(aminosulfonyl)-N-(3,5-dimethyl-4-isoxazolyl)-
• CAS NO: 681808-48-0
• Molecular Formula: C9H13N3O4S
• Molecular Weight: 259.28222
• Product Categories: AMIDE
• Mol File: 681808-48-0.mol

Chemical Properties

• Appearance: /
• Density: 1.50±0.1 g/cm3(Predicted)
• PKA: 9.33±0.20(Predicted)
• CAS DataBase Reference: Cyclopropanecarboxamide, 1-(aminosulfonyl)-N-(3,5-dimethyl-4-isoxazolyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxamide, 1-(aminosulfonyl)-N-(3,5-dimethyl-4-isoxazolyl)-(681808-48-0)
• EPA Substance Registry System: Cyclopropanecarboxamide, 1-(aminosulfonyl)-N-(3,5-dimethyl-4-isoxazolyl)-(681808-48-0)

Safety Data

• Hazardous Substances Data: 681808-48-0(Hazardous Substances Data)

Upstream product

• 681808-47-9 1-(3,5-dimethylisoxazol-4-yl)carbamoylcyclopropanesulfonamide tert-butyl carbamate 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.